Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Samsung Electronics: Seventh-generation HBM4E mass production to start in the first half of next year

Samsung Electronics: Seventh-generation HBM4E mass production to start in the first half of next year

404k404k2026/11/01 13:19
Show original
Samsung Electronics: "Seventh-generation HBM4E mass production to start in the first half of next year, foundry business achieves double-digit growth"Samsung Electronics’ HBM4 revenue in the third quarter increased to more than three times the previous quarter. The next observation point is whether the expansion of existing products can continue through to 2027 with HBM4E mass production and foundry business growth.HBM is high-bandwidth memory used for AI accelerators. Samsung Electronics stated that it shipped 12-layer HBM4E samples to customers in May this year, and now plans to begin mass production in the first half of 2027 and boost output in the second half. The average selling price of DRAM increased by 20% quarter-on-quarter in the third quarter, and NAND rose by 10%.Foundry business revenue is linked to chips under HBM known as base dies. Samsung Electronics expects foundry revenue in the fourth quarter to achieve double-digit growth both quarter-over-quarter and year-over-year.According to the company’s financial data, mobile and network business posted an operating loss of 600 billion KRW in the third quarter, and finished goods business continues to face cost pressure.The mass production schedule and foundry growth are part of company plans, not yet realized results. It is necessary to pay attention to HBM4E customer certification and actual shipments, as well as whether increased output can translate into profitability.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56

Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.

After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.

智通财经•2026/11/06 07:53

Hong Kong live music service provider Guitar Group applies for US IPO, aiming to raise $31 million

Guitar Group, a provider of music performance events, guitar-making workshops, and guitar repair services, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, seeking to raise up to $31 million through an initial public offering (IPO).

智通财经•2026/11/06 07:50